Top 5 Life Science Angel Investors in Belgium in September 2025
A list of 5 angel investors that invest in Life science startups based in Belgium. We rank investors based on the number of investments they made in Life science companies from Belgium. We update this investor list every month.Top 5 Life Science Angel Investors in Belgium in September 2025
Investor | Life Science Belgium investments |
---|---|
Luc Vauterin | 2 |
Pierre Drion | 2 |
Kenneth Buckfire | 1 |
Annie Vereecken | 1 |
Evren Ucok | 1 |
Luc Vauterin - Board Member @ ONTOFORCE
Show more
Investment focus
- Life Science, Data Integration, Data Visualization
- Seed, Series A
- Belgium
Portfolio highlights
- ONTOFORCE — ONTOFORCE creates and implements pioneering semantic search technology for information management. Our user-friendly data search platform DISQOVER builds uniquely intelligent links between heterogeneous data sources, allowing everybody to become a data scientist.
Pierre Drion - CEO @ Petercam
Show more
Investment focus
- Biotechnology, Health Care, Life Science
- Series A, Series B, Funding Round
- Belgium
Portfolio highlights
- A-Mansia Biotech — A-Mansia Biotech is a developer of products based on the properties of the Akkermansia muciniphila (A. muciniphila) bacterium. The company's nutritional supplement based on a gut bacterium called Akkermansia, the population of microorganisms housed in the gastrointestinal tract. A. muciniphila is located in the mucus layer covering theintestinal epithelium, which allows the bacterium to establish a close cross-talk with the host.
- Novadip Biosciences — Novadip Biosciences, an advanced biopharmaceutical company focused on new generation of therapies from adipose stem cells adapted to hard and soft tissues reconstruction.
- Santero Therapeutics — This is the homepage of the website
Kenneth Buckfire is the Chief Executive Officer at Miller Buckfire.
Show more
Investment focus
- Medical, Health Care, Life Science
- Series A
- Belgium
Portfolio highlights
- Amyl Therapeutics — Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β(Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases.
Annie Vereecken
Show more
Investment focus
- Biotechnology, Medical, Hospital
- Seed, Series A, Funding Round
- Belgium
Portfolio highlights
- Ziphius — Ziphius Vaccines is a biopharmaceutical company dedicated to developing next-generation vaccines for the prevention of infectious diseases.
- Sensolus — Sensolus provides care-free tracking of your valuable non-powered assets directly from the cloud.Sensolus offers turnkey solutions for wireless, low-power context-aware sensing. Sensolus developed a personal product line of low-power tracker systems called STICKNTRACK.Sensolus is built upon many years of expertise in low-power networks,wireless sensor design, cloud-based sensor management, analytics, and applications.
- Allegro Biotech — Allegro has developed the world’s-first custom-tailored, durable, biocompatible, anisotropic, regenerative meniscus cartilage, providing immediate support while also leverage the body’s own healing potential to regenerate human cartilage (proliferation and differentiation of fibrochondrocyte cells).
Evren Ucok is a co-founder and investor at Peak Games, an interactive social game development platform.
He is also a partner at Earlybird Venture Capital, an investment fund-based in Europe that focuses on emerging companies; Trendyol.com, a fashion e-commerce site; and Oliver Wyman.
Show more
Investment focus
- Medical, Health Care, Life Science
- Series A
- Turkey, Belgium
Portfolio highlights
- idemama — Idemama is an online platform that provides its users with web and graphic design services. It is based in Istanbul, Turkey.
- Amyl Therapeutics — Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β(Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases.
Investors by industry
Google
Marketplace
Hardware
Energy
Proptech
Health Care
Biotech
Artificial intelligence
Climate
Consumer
Community
Impact
Gaming
FinTech
EdTech
Sustainability
Venture Capital
Big Data
Web3
B2B
Financial Services
Finance
Infrastructure
Education
Photography
Payments
Food and Beverage
Video Games
Organic Food
Retail
Beauty
Publishing
Clean Energy
Real Estate
Manufacturing
Art
Music
Android
Internet
Enterprise Software
eSports
Franchise
Sports
Construction
Digital Media
Email
Medical
Social Network
Wellness
Social Media
Mobile
Legal
Local
Recruiting
Cannabis
Platforms
Fitness
Travel
Mobile Advertising
Biotechnology
Hospitality
Social
Automotive
Crowdfunding
Wine And Spirits
Medical Device
CleanTech
Transportation
Mobile Apps
InsurTech
Enterprise
LGBT
Fashion
Oil and Gas
Life Science
Theatre
Film
Non Profit
Renewable Energy
SaaS
Sporting Goods
Restaurants
Social Impact
Software
Celebrity
Cryptocurrency
Machine Learning
Agriculture (agtech)
Media (entertainment)
Facebook
Blockchain
Investors by country
United Kingdom
Canada
South Korea
Ireland
United States
New Zealand
India
Germany
Australia
Armenia
South Africa
Spain
Japan
Africa
China
Sri Lanka
Singapore
Qatar
Asia
Indonesia
Vietnam
Oceania
LATAM
Middle East
Europe
Saudi Arabia
Brazil
Bulgaria
Belize
Bahrain
Croatia
Georgia
Belarus
Hungary
France
Ghana
Ethiopia
Gibraltar
Chile
Egypt
Finland
Costa Rica
Greece
Barbados
Belgium
Estonia
Liechtenstein
Liberia
Lebanon
Mauritius
Peru
Norway
Israel
Malaysia
Mexico
Nicaragua
Jersey
Panama
Morocco
Mali
Lithuania
Italy
Philippines
Kuwait
Malta
Myanmar
Sierra Leone
El Salvador
Uganda
Venezuela
Sweden
Slovenia
Poland
Uruguay
Ukraine
Tajikistan
Puerto Rico
Portugal
Tunisia
Taiwan
Tanzania
Turkey
San Marino
Senegal
Togo
Uzbekistan
Serbia
Russian Federation
Zambia
Rwanda
Zimbabwe
Thailand
Dominican Republic
Bermuda
Azerbaijan
Iceland
Nigeria
Czech Republic
Bahamas
Namibia
Iraq
United Arab Emirates
Denmark
Jamaica
Honduras
Algeria
Hong Kong
Ecuador
Isle of Man
Bolivia
Faroe Islands
Grenada
Luxembourg
Pakistan
Albania
Jordan
Romania
Bangladesh
Argentina
Kenya
Kazakhstan
Cayman Islands
Cambodia
Oman
Latvia
Cyprus
Austria
Switzerland
Cameroon
Colombia
Guatemala
Seychelles
Marshall Islands
Angel Investors in Belgium by industry
Biotechnology
Marketplace
Food and Beverage
Financial Services
Big Data
Finance
Life Science
Medical
Medical Device
Internet
Social Media
Manufacturing
Software
Sports
Enterprise Software
Mobile Advertising
Hospitality
Automotive
FinTech
Enterprise
Health Care
Biotech
Climate
SaaS
Community
Gaming
Real Estate
Publishing
Transportation
Retail
Legal
Platforms
Payments
Proptech
Artificial intelligence
Hardware
Media (entertainment)
Construction
Machine Learning
Energy
Mobile